Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CX3CR1 | P49238 | 14/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 13/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.39 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12165799 | 0.80 | KDM4E (0.59) | KDM4ENPSR1L3MBTL1ADORA1MEN1 | |
| SCHEMBL2324652 | 0.76 | KDM4E (0.43) | KDM4ENPSR1L3MBTL1MEN1ALDH1A1 | |
| SCHEMBL2814275 | 0.74 | KDM4E (0.51) | KDM4ENPSR1L3MBTL1MEN1ALDH1A1 | |
| SCHEMBL2815178 | 0.74 | KDM4E (0.51) | KDM4ENPSR1L3MBTL1MEN1ALDH1A1 | |
| SCHEMBL12165806 | 0.74 | LMNA (0.50) | KDM4ENPSR1L3MBTL1CX3CR1MAPK1 | |
| SCHEMBL3654673 | 0.72 | KDM4E (0.43) | KDM4ENPSR1L3MBTL1MEN1ALDH1A1 | |
| SCHEMBL1259522 | 0.70 | KDM4E (0.76) | KDM4ENPSR1L3MBTL1MEN1ALDH1A1 | |
| SCHEMBL18109581 | 0.69 | TLR8 (0.76) | CX3CR1CXCR2TLR8TLR7 | |
| SCHEMBL18109579 | 0.69 | TLR8 (0.76) | CX3CR1CXCR2TLR8TLR7 | |
| SCHEMBL438046 | 0.69 | KDM4E (0.44) | KDM4ENPSR1L3MBTL1MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2357184-B1 | Imidazoquinoxaline compounds as immunomodulators | NOVARTIS AG (CH) | 2015-02-25 | — | — | EP | disclosed |
| US-20130101622-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20130101622-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| US-8173657-B2 | Imidazoquinoxaline compounds as immunomodulators | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173657-B2 | Imidazoquinoxaline compounds as immunomodulators | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| US-8173657-B2 | Imidazoquinoxaline compounds as immunomodulators | NOVARTIS AG (CH) | 2012-05-08 | — | — | US | disclosed |
| EP-2010537-B1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| EP-2010537-B1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| EP-2357184-A1 | Imidazoquinoxaline compounds as immunomodulators | Novartis AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357184-A1 | Imidazoquinoxaline compounds as immunomodulators | Novartis AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20090311288-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090311288-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090311288-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| EP-2010537-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | Novartis AG (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007109813-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007109813-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | NOVARTIS AG (CH) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130101622-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | IFNG, MYD88, IRF3 | KDM4E 1394/4885NPSR1 3212/4885L3MBTL1 4776/4885 |
| US-20090311288-A1 | IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS | IFNG, MYD88, IRF3 | KDM4E 800/4885NPSR1 2240/4885L3MBTL1 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.